Further strengthen the whole chain supervision of traditional Chinese medicine The quality of traditional Chinese patent medicines and simple preparations has been significantly improved Supervision | traditional Chinese medicine | chain
CCTV News: The "2022 National Traditional Chinese Medicine Regulatory Blue Book", compiled and distributed under the guidance of the National Medical Products Administration, was released today. According to the blue book, in 2022, 5805 batches of 47 varieties of traditional Chinese patent medicines and simple preparations will be sampled and inspected by the state, and the qualification rate will be 99.3%.
According to the 2022 National Blue Book on the Supervision of Traditional Chinese Medicine, as of May 2023, there are about 2400 traditional Chinese patent medicines and simple preparations manufacturers in China, about 9000 varieties of traditional Chinese medicine, and about 57000 valid approval numbers, basically meeting the public's clinical drug demand.
Zhao Junning, Deputy Director of the State Food and Drug Administration: The results of national drug sampling inspection in recent five years show that the quality of traditional Chinese patent medicines and simple preparations has improved significantly since 2019, and the qualification rate has remained above 99%. We will carry out national drug sampling and quality monitoring of traditional Chinese medicine according to the annual plan, comprehensively analyze the sampling monitoring data, and strengthen the monitoring of adverse reactions of traditional Chinese medicine. Organize research and development of Chinese medicine adverse reaction signal monitoring tools that conform to the characteristics of traditional Chinese medicine, and conduct comprehensive analysis and judgment of safety risk signals discovered in a timely manner.
It is reported that China's traditional Chinese medicine supervision has a wide scope, long chain, and multiple links, covering not only categories such as traditional Chinese medicine, traditional Chinese medicine decoction pieces, traditional Chinese medicine formula granules, and traditional Chinese medicine preparations, but also involves breeding, processing, production, sales, and use. Therefore, consolidating and improving the full chain supervision system from standardized planting to clinical use has become the primary task of current traditional Chinese medicine supervision.
![Further strengthen the whole chain supervision of traditional Chinese medicine The quality of traditional Chinese patent medicines and simple preparations has been significantly improved Supervision | traditional Chinese medicine | chain](https://a5qu.com/upload/images/d1f5eaa43749e4fd253a9586eea24506.jpg)
Next, the National Medical Products Administration will strengthen risk management, enhance the full chain supervision of traditional Chinese medicine, adverse reaction monitoring, and post market evaluation, and take corresponding risk control measures to adhere to the safety bottom line, promote the inheritance, innovation, and high-quality development of traditional Chinese medicine.